Floatz logo

Glycerol Phenylbutyrate

Developmental and Epileptic Encephalopathy

Weill Medical College of Cornell UniversitySmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Developmental and Epileptic Encephalopathy cohort.

Asset / SponsorPhaseRating
Bexicaserin
Longboard Pharmaceuticals
Phase 3BB
Benzeneethanamine, N-ethyl-?-methyl-4-(trifluoromethyl)-, hydrochloride, (±)-
Zogenix, Inc.
Phase 3BB
Elsunersen
Praxis Precision Medicines
Phase 3B
Nbi-827104
Neurocrine Biosciences
Phase 2CCC
MELATONIN
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2CCC

View all 9 →

Same molecule, other indications

Glycerol Phenylbutyrate is also rated in:

hepatic encephalopathyDormant
B
Indicative ·
61 / 100
View asset →
cirrhosis of liverDormant
CCC
Indicative ·
54 / 100
View asset →
urea cycle disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →